Myriad Genetics announced seven new commercial coverage decisions for Prolaris, the company’s market leading prognostic test for patients with prostate cancer.The payers include a top-25 commercial insurer in the United States and in aggregate the payers represent six million new covered lives for Prolaris. These decisions follow the recently updated National Comprehensive Cancer Network NCCN, guidelines that support Prolaris as standard of care in making treatment decisions for patients with low and favorable-intermediate risk prostate cancer.”We are extremely pleased to see accelerating commercial insurer coverage for Prolaris based upon the strong supporting clinical evidence which was underscored by recent NCCN guidelines,” said Nicole Lambert, general manager, Urology. “These decisions will ensure broader patient access to Prolaris allowing for more informed clinical decision making and lower overall healthcare costs to the system.”In aggregate, Prolaris now has insurance coverage for approximately 50% of Prostate cancer patients in the United States. Over 60,000 men have received the Prolaris test to help guide their treatment for prostate cancer.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.